Nxera Q3 FY2026: Returns to profit as partnership income grows

Nxera reported revenue of ¥27.742 billion for January to September 2026, up 27.0% from a year earlier. Operating profit was ¥3.175 billion and profit attributable to owners of the parent was ¥2.328 billion, both reversing losses a year earlier. Basic earnings per share improved to ¥25.61 from a loss of ¥53.31 a year earlier.

Revenue growth was the biggest tailwind, particularly as income from development milestones achieved by partners rose sharply from a year earlier. Research and development expenses fell as several programs advanced to their next stages and the company narrowed its focus areas. Core operating profit turned positive at ¥9.818 billion, compared with a loss of ¥986 million a year earlier. Impairments, including goodwill, and restructuring costs, however, meant core operating profit differed from IFRS operating profit.

Nxera reports a single pharmaceutical segment, so the breakdown below shows revenue by product sales and other categories. Sales and royalty revenue from marketed products rose 14.9% year on year, while research and development revenue increased 47.6%.

QUVIVIQ performed well as a treatment for insomnia, with royalties and product supply revenue from Shionogi increasing. Pivlaz also continued to benefit from higher sales of its treatment for cerebral vasospasm. Royalties on Novartis respiratory disease products declined as the portfolio matured. Research and development revenue benefited from 10 milestone achievements, up from six a year earlier, offsetting a decline in upfront payments.

Nxera forecasts FY2026 revenue of ¥33.8 billion to ¥48.8 billion, up 14.1% to 64.8% from the previous year. Operating profit is projected at ¥700 million to ¥15.7 billion, and core operating profit at ¥7.8 billion to ¥22.8 billion. The company made no changes to its latest outlook.

The lower end of the forecast assumes about ¥12.5 billion in milestone income from existing partners and roughly ¥3.5 billion in cuts to research and development, selling, general and administrative expenses. The upper end also assumes an upfront payment from a major new partnership, making the timing and terms of any deal a significant factor for results. Foreign-exchange assumptions are ¥152 to the dollar and ¥200 to the pound.

Total assets stood at ¥130.252 billion at the end of September, down ¥4.535 billion from the end of the previous fiscal year. The equity ratio attributable to owners of the parent rose to 49.3% from 45.3% at the prior year-end.

Operating cash flow turned positive, supported by milestone receipts. Investment spending increased with the acquisition of intangible assets related to the introduction of vamorolone and an investment in an affiliate, while debt repayments continued. Cash and cash equivalents consequently fell ¥3.752 billion from the prior year-end to ¥16.613 billion. Nxera forecasts no annual dividend for FY2026, unchanged from the previous year. The company recorded ¥1.25 billion in share repurchases on a year-to-date basis, but its earnings release did not announce a new buyback authorization.

Nxera is pursuing two growth pillars: building its introduced-product business in Japan and the Asia-Pacific region, and drug discovery and partnerships through its NxWave platform. In the first nine months of 2026, the company achieved 10 milestones tied to partners' clinical development and research progress, supporting revenue growth.

• Partner development progress: Clinical trials advanced for candidates including a Neurocrine drug for schizophrenia, generating multiple milestone payments. Development progress on a Centessa-related orexin 2 receptor agonist also generated revenue.
• Expanding sales territories: In October, Nxera signed an exclusive licensing, supply and commercialization agreement with Taiwan's Synmosa for QUVIVIQ in eight Asia-Pacific countries.
• Expansion into rare diseases: Nxera filed for approval in South Korea for vamorolone, a treatment for DMD, and is targeting approval in 2027 and a 2028 launch. For lucerastat, a Fabry disease drug candidate, the company obtained rights in parts of Asia-Pacific and agreed to pay an upfront fee of 7 million Swiss francs.

These partnerships and licensing deals are intended to broaden the marketed portfolio and development pipeline while limiting the burden of developing products alone. Milestone income, however, depends on development progress and contract terms, so it can vary from year to year. Revenue stability will depend on growing sales of existing products and steadily advancing introduced products through approval and launch.

Nxera has returned to profitability, but revenue includes payments that can fluctuate with partners' development progress and whether upfront fees are received. The company has also said it cannot guarantee it will meet its forecasts, making progress in development and sales important to monitor.

• Volatility in milestone income: Delays in partners' clinical trials or research could shift the timing of revenue recognition and affect the company's ability to meet its full-year forecast.
• Clinical development and regulatory uncertainty: Trial results and regulatory decisions could alter development plans or launch timelines for Nxera's and its partners' drug candidates.
• Product sales and competition: Pivlaz and QUVIVIQ sales are growing, but royalties could vary as products mature and depending on the competitive landscape.
• Impairments and declining cash: Nxera recorded impairments, including goodwill, in the current period, and its cash balance fell from the previous year-end. Managing investment in introduced products and development alongside available financial resources remains a challenge.
• Foreign-exchange fluctuations: Research and development overseas, including in the U.K., and contracts denominated in foreign currencies expose expenses and revenue to movements in the yen against the pound and U.S. dollar.